Aptar Pharma and Kali Care have entered into a partnership to combine Aptar Pharma’s ophthalmic device expertise with Kali Care’s digital monitoring system for ophthalmic medications.
Using eye drops as a drug delivery system presents its own set of challenges which must be recognised and addressed at the clinical level.
With soaring clinical trial costs and complexity, the biopharmaceutical industry is constantly seeking new approaches to improve efficiency.
For ophthalmologists, the ability to see the medication adherence score of patients with glaucoma is a powerful tool in managing treatment plans.
Kali Care, a technology company, based in Silicon Valley (USA), has developed the first digital monitoring system for ophthalmic medications. The monitoring technology integrates smart sensors, data analytics and cloud services.
This technology allows ophthalmologists to distinguish patients requiring minimal support from those who require closer monitoring.
In clinical trials, the Kali Care system replaces usage assumptions and self-reporting, opening new opportunities for the monitoring of patient adherence.
The Kali Care Adherence Score provides critical information for explaining the incongruity between recommended treatment and actual treatment outcomes.
In a joint statement, Salim Haffar, President of Aptar Pharma and Sina Fateh, Founder and CEO of Kali Care, highlighted the advantages associated with combining microbiological safety and sensor technology.
“Clinicians are now able to rely on objective and accurate data. Aptar Pharma’s leading dispensing technologies combined with Kali Care’s smart sensors, data analytics and cloud services will help make clinical trials more efficient and effective.”
“This allows ophthalmologists to improve risk strategies to distinguish patients requiring minimal support from those who require closer monitoring.”